Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15145489 | 0.81 | HPGD (0.46) | DGAT1TSHRHPGDALDH1A1RAB9A | |
| SCHEMBL966670 | 0.81 | ALDH1A1 (0.40) | GAATSHRHPGDALDH1A1KDM4E | |
| SCHEMBL932912 | 0.81 | ALDH1A1 (0.40) | GAATSHRHPGDALDH1A1KDM4E | |
| SCHEMBL18192896 | 0.77 | KDM4E (0.37) | GAATSHRHPGDALDH1A1KDM4E | |
| SCHEMBL21764438 | 0.77 | HPGD (0.36) | DGAT1GAATSHRHPGDALDH1A1 | |
| SCHEMBL20271951 | 0.75 | DGAT1 (0.33) | DGAT1GAAHPGDALDH1A1NPC1 | |
| SCHEMBL17962978 | 0.74 | TERT (0.39) | DGAT1GAAHPGDALDH1A1NPC1 | |
| SCHEMBL18498599 | 0.74 | CES2 (0.47) | TSHRHPGDALDH1A1HSD17B10RAB9A | |
| SCHEMBL967567 | 0.74 | TDP1 (0.48) | GAAHPGDALDH1A1KDM4ENPC1 | |
| SCHEMBL18032970 | 0.73 | HPGD (0.36) | DGAT1HPGDALDH1A1KDM4EPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3010925-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-3010925-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-3010925-A1 | BACE INHIBITORS | Eli Lilly & Company (US) | 2016-04-27 | — | — | EP | disclosed |
| US-9169271-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169271-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169271-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150210716-A1 | BACE INHIBITORS | LILLY CO ELI (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210716-A1 | BACE INHIBITORS | LILLY CO ELI (US) | 2015-07-30 | — | — | US | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2451793-A1 | BACE INHIBITORS | Eli Lilly and Company (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005738-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005738-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | DGAT1 2179/4885GAA 22/4885TSHR 4824/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | DGAT1 2179/4885GAA 22/4885TSHR 4824/4885 |
| US-20150210716-A1 | BACE INHIBITORS | BACE1, BACE2, APP | DGAT1 3798/4885GAA 48/4885TSHR 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.